The open structure of a multi-drug-resistant HIV-1 protease is stabilized by crystal packing contacts

被引:34
作者
Layten, Melinda
Hornak, Viktor
Simmerling, Carlos [1 ]
机构
[1] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA
[2] SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA
[3] SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA
[4] Brookhaven Natl Lab, Computat Sci Ctr, Upton, NY 11973 USA
关键词
D O I
10.1021/ja065133k
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The introduction of HIV-1 protease (HIV-PR) inhibitors has led to a dramatic increase in patient survival; however, these gains are threatened by the emergence of multi-drug-resistant strains. Design of inhibitors that overcome resistance would be greatly facilitated by deeper insight into the mechanistic events associated with binding of substrates and inhibitors, as well as an understanding of the effects of resistance mutations on the structure and dynamic behavior of HIV-PR. We previously reported a series of simulations that provide a model for HIV-PR dynamics, with spontaneous conversions between the bound and unbound crystal forms upon addition or removal of an inhibitor. Importantly, the unbound protease transiently sampled a third fully open state that permits entry to the active site, unlike both crystallographic forms. Recently, a crystal structure of unbound HIV-PR was reported for the MDR 769 isolate (PDB: 1TW7); unlike all previous experimental structures, the binding pocket is open. It is suggested that drug resistance in this strain arises at least in part from the inability of inhibitors to induce closing. We carried out simulations of the MDR 769 HIV-PR mutant and observed that the reported structure is unstable in solution and rapidly adopts the semi-open conformation observed for the unbound wild-type protease in solution. Further analysis suggests that the wide-open structure observed for MDR 769 arises not from sequence variation, but instead is an artifact from crystal packing. Thus, despite being the first experimental structure to reveal flap opening sufficient for substrate access to the active site, this structure may not be directly relevant to studies of inhibitor entry or to the cause of HIV-PR drug resistance. Copyright © 2006 American Chemical Society.
引用
收藏
页码:13360 / 13361
页数:2
相关论文
共 14 条
[1]   Rapid structural fluctuations of the free HIV protease flaps in solution: Relationship to crystal structures and comparison with predictions of dynamics calculations [J].
Freedberg, DI ;
Ishima, R ;
Jacob, J ;
Wang, YX ;
Kustanovich, I ;
Louis, JM ;
Torchia, DA .
PROTEIN SCIENCE, 2002, 11 (02) :221-232
[2]   HIV-1 protease flaps spontaneously close to the correct structure in simulations following manual placement of an inhibitor into the open state [J].
Hornak, V ;
Okur, A ;
Rizzo, RC ;
Simmerling, C .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (09) :2812-2813
[3]   HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations [J].
Hornak, V ;
Okur, A ;
Rizzo, RC ;
Simmerling, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (04) :915-920
[4]   VMD: Visual molecular dynamics [J].
Humphrey, W ;
Dalke, A ;
Schulten, K .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 1996, 14 (01) :33-38
[5]   RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS [J].
LAM, PYS ;
JADHAV, PK ;
EYERMANN, CJ ;
HODGE, CN ;
RU, Y ;
BACHELER, LT ;
MEEK, JL ;
OTTO, MJ ;
RAYNER, MM ;
WONG, YN ;
CHANG, CH ;
WEBER, PC ;
JACKSON, DA ;
SHARPE, TR ;
ERICKSONVIITANEN, S .
SCIENCE, 1994, 263 (5145) :380-384
[6]   Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms - Structure/function relationship and influence of crystal packing [J].
LangeSavage, G ;
Berchtold, H ;
Liesum, A ;
Budt, KH ;
Peyman, A ;
Knolle, J ;
Sedlacek, J ;
Fabry, M ;
Hilgenfeld, R .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 248 (02) :313-322
[7]   Wide-open 1.3 Å structure of a multidrug-resistant HIV-1 protease as a drug target [J].
Martin, P ;
Vickrey, JF ;
Proteasa, G ;
Jimenez, YL ;
Wawrzak, Z ;
Winters, MA ;
Merigan, TC ;
Kovari, LC .
STRUCTURE, 2005, 13 (12) :1887-1895
[8]   Restrained molecular dynamics simulations of HIV-1 protease: The first step in validating a new target for drug design [J].
Perryman, AL ;
Lin, JH ;
McCammon, JA .
BIOPOLYMERS, 2006, 82 (03) :272-284
[9]   HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs [J].
Perryman, AL ;
Lin, JH ;
McCammon, JA .
PROTEIN SCIENCE, 2004, 13 (04) :1108-1123
[10]   THE 3-DIMENSIONAL STRUCTURE OF THE ASPARTYL PROTEASE FROM THE HIV-1 ISOLATE BRU [J].
SPINELLI, S ;
LIU, QZ ;
ALZARI, PM ;
HIREL, PH ;
POLJAK, RJ .
BIOCHIMIE, 1991, 73 (11) :1391-1396